AMZN
NVO
Medicare finally loosens the door
The Centers for Medicare & Medicaid Services is rolling out a new Medicare GLP-1 Bridge program that lets eligible patients with obesity access Wegovy for a $50 monthly copay starting July 1st. The deal covers Wegovy injections and tablet formulations nationwide through the end of 2027, which is a pretty chunky stamp of approval for Novo Nordisk’s obesity franchise.
Why investors should care
This is the kind of policy shift that can turn a drug from “hot” to “everywhere” fast. If you’ve been tracking GLP-1 demand, you know the bottleneck hasn’t exactly been consumer interest — it’s been access, coverage, and who’s footing the bill. A Medicare-backed pathway could widen the market and give Novo a bigger runway for Wegovy, especially with millions of beneficiaries in the mix.
Amazon’s pharmacy side quest
As if the GLP-1 story wasn’t already busy enough, Amazon Pharmacy also said it’s expanding access to Novo Nordisk’s oral Ozempic, with same-day delivery in nearly 3,000 U.S. cities and towns and a plan to get to almost 4,500 by year-end. Customers paying with insurance could see prices as low as $25 a month, while cash-pay pricing starts at $149 after savings.
Amazon is also testing in-office pickup kiosks at select One Medical locations, which is very on-brand: fewer pharmacy lines, more “why not have the medication waiting for me after my appointment?” energy. Big picture: Novo is getting another meaningful access win, and Amazon is turning pharmacy logistics into yet another aisle in its empire.